Science, Discovery, Tech and Environment · 17 November 2026
Indian Institute of Science team finds antibiotic pairing that reverses isoniazid resistance in TB
Exam-focused facts from the 17 November 2026 current affairs briefing.
Key facts
- Researchers at the Indian Institute of Science (IISc), Bengaluru, found that pairing the frontline TB drug isoniazid with the antibiotic vancomycin can reverse isoniazid resistance in laboratory tests and in mice.
- The study, titled 'Vancomycin rescues sensitivity to isoniazid in clinical isolates of drug-resistant Mycobacterium tuberculosis', was published in Microbiology Spectrum by IISc's department of biochemistry.
- Isoniazid is a prodrug requiring activation by a bacterial enzyme, and gene mutations can block this activation, allowing bacteria to survive; vancomycin normally cannot cross the impermeable cell wall of M. tuberculosis, but the drug combination compromises cell wall integrity, letting vancomycin enter and kill the bacteria.
- The team tested isolates from sputum samples of drug-resistant TB patients in collaboration with the National Tuberculosis Institute, Bengaluru, and most isolates, including isoniazid-resistant and multidrug-resistant (MDR) strains, showed more than 90% reduction in bacterial growth with the combination.
- In mice infected with MDR M. tuberculosis and treated for 10 days, the combination cut bacterial load about 10-fold in both lungs and spleen and reduced lung granulomas, while neither drug alone significantly reduced bacterial burden.
- Nagasuma Chandra, professor at IISc's department of biochemistry, is the corresponding author; Sukriti Pal is the first author, with co-authors including Amit Singh of IISc's Centre for Infectious Disease Research and Shalini Birua.
- The combination is not yet ready for patient use; the team is working to advance it towards clinical trials, which Pal said need to be conducted on drug-resistant TB cases.